Hilary van der Hoff
Vice President of IP
Hilary is the Vice President of Intellectual Property at T-Therapeutics, bringing extensive expertise as an IP advisor in the biotech industry.
Previously, Hilary was Director of IP at Kymab, where her responsibilities included the IP for Kymab’s bispecific antibody platform and pipeline, heavy-chain antibody platform, infectious disease and vaccines group and alomfilimab clinical program.
Following Kymab’s acquisition by Sanofi for US$1.45 billion in 2021, Hilary integrated into the Global IP Department of Sanofi. Hilary’s prior roles include Patent Counsel at IONTAS and Partner in the biotechnology group at IP firm Mewburn Ellis LLP.
She holds a first-class degree in Molecular and Cellular Biochemistry from the University of Oxford.
